RAB25 and triple-negative breast carcinoma: Likewise, antibody-drug conjugates that can target these tumors and deliver a synthetically lethal payload to exploit the loss of the rab25 pathway may be an effective therapeutic strategy to target this subset of ras mutant triple-negative breast cancers.